{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:45:54Z","timestamp":1777020354149,"version":"3.51.4"},"reference-count":101,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/14656566.2026.2652459","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:13:49Z","timestamp":1774858429000},"page":"365-378","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update"],"prefix":"10.1080","volume":"27","author":[{"given":"Leyken","family":"Wilson","sequence":"first","affiliation":[{"name":"Regis University","place":["Denver, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"CHRISTUS St. Vincent Regional Medical Center","place":["Santa Fe, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3727-952X","authenticated-orcid":false,"given":"Daniel J.","family":"Berlau","sequence":"additional","affiliation":[{"name":"Regis University","place":["Denver, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Venugopal V Pavlakis S. Duchenne muscular dystrophy. StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Jan 8]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482346\/"},{"key":"e_1_3_4_4_1","unstructured":"Duchenne muscular dystrophy - symptoms causes treatment | NORD [internet]. [cited 2026 Jan 8]. Available from: https:\/\/rarediseases.org\/rare-diseases\/duchenne-muscular-dystrophy\/"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-022-02996-8"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/374176"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2040-4603.2015.tb00638.x"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004347"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01862-w"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-020-00613-8"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012910"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200556"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2394578"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-693X(25)00253-2"},{"key":"e_1_3_4_17_1","unstructured":"PJ-Nicholoff-Steroid-Protocol.pdf [Internet]. [cited 2026 Jan 8]. Available from: https:\/\/www.parentprojectmd.org\/wp-content\/uploads\/2018\/03\/PJ-Nicholoff-Steroid-Protocol.pdf"},{"key":"e_1_3_4_18_1","unstructured":"Connolly AM. Phase-2 trial of 5mg\/kg\/week prednisolone in young boys with DMD [internet]. Report No.: nCT05412394. clinicaltrials.gov; 2025 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05412394"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003049"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003217"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26736"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28309"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210776"},{"key":"e_1_3_4_24_1","unstructured":"Mah JK Clemens PR Guglieri M et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy. [cited 2026 Jan 8]."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.125331"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07939-1"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae521"},{"key":"e_1_3_4_29_1","unstructured":"Hoffmann-La R. A phase II multicenter open-label study to evaluate the efficacy safety pharmacokinetics and pharmacodynamics of Satralizumab in pediatric patients with duchenne muscular dystrophy (SHIELD DMD) [internet]. Report No.: nCT06450639. clinicaltrials.gov; 2026 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06450639"},{"key":"e_1_3_4_30_1","unstructured":"Gr\u00fcnenthal Gmb H. An open-label single-center trial evaluating the safety tolerability and pharmacokinetics of a single dose of GRT6019 including food effect in healthy male participants [internet]. Report No.: nCT07317063. clinicaltrials.gov; 2025 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07317063"},{"key":"e_1_3_4_31_1","unstructured":"Spurney C. A single escalating dose Pilot trial of canakinumab (ILARIS\u00ae) assessing safety and biomarker changes in boys with duchenne muscular dystrophy [internet]. Report No.: nCT03936894. clinicaltrials.gov; 2023 [cited 2026 Jan 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03936894"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00665-2"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-024-00494-6"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01423-y"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22758"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crtox.2024.100182"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210643"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/22143602251366721"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28075"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009233"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2021.0043"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221656"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040912"},{"key":"e_1_3_4_45_1","unstructured":"Dystrophy PPM. Sarepta announces completion of ESSENCE trial for exon 45 & 53 skipping therapies [internet]. Parent Proj. Muscular Dystrophy. 2025 [cited 2026 Jan 14]. Available from: https:\/\/www.parentprojectmd.org\/sarepta-announces-completion-of-essence-trial-for-exon-45-53-skipping-therapies\/"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.190"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv155"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031303"},{"key":"e_1_3_4_49_1","unstructured":"Community letter: update SRP-5051 program | sarepta therapeutics [internet]. [cited 2026 Jan 13]. Available from: https:\/\/www.sarepta.com\/community-letter-update-srp-5051-program"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2025.104457"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102759"},{"key":"e_1_3_4_52_1","unstructured":"Commissioner O of the. FDA expands approval of gene therapy for patients with duchenne muscular dystrophy [internet]. FDA; 2024 [cited 2026 Jan 12]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1167762"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03304-z"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-025-02758-6"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2060737"},{"key":"e_1_3_4_57_1","unstructured":"Hoofnagle JH. Delandistrogene Moxeparvovec. LiverTox Clin Res Inf Drug-induc liver inj [internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [cited 2026 Jan 8]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK618387\/"},{"key":"e_1_3_4_58_1","unstructured":"Commissioner O of the. FDA approves new safety warning and revised indication that limits use for elevidys following reports of fatal liver injury [internet]. FDA; 2025 [cited 2026 Jan 8]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230185"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03750-3"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.06.031"},{"key":"e_1_3_4_62_1","unstructured":"Pfizer provides update on phase 3 study of investigational gene therapy for ambulatory boys with duchenne muscular dystrophy [internet]. [cited 2026 Jan 12]. Available from: https:\/\/investors.pfizer.com\/Investors\/News\/news-details\/2024\/Pfizer-Provides-Update-on-Phase-3-Study-of-Investigational-Gene-Therapy-for-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy\/default.aspx"},{"key":"e_1_3_4_63_1","unstructured":"Sardocor Corp. A phase 1b open-label controlled trial evaluating the safety and efficacy of SRD-001 (AAV1\/SERCA2a) in subjects with cardiomyopathy secondary to duchenne muscular dystrophy [internet]. Report No.: nCT06224660. clinicaltrials.gov; 2025 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06224660"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31611-2"},{"key":"e_1_3_4_65_1","unstructured":"PTC. Therapeutics provides regulatory update on TranslarnaTM (ataluren) in Europe | PTC therapeutics Inc. [internet]. [cited 2026 Jan 31]. Available from: https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-provides-regulatory-update-translarnatm-1"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0238"},{"key":"e_1_3_4_67_1","unstructured":"Andrea. Update to the U.S. Duchenne community on the ataluren (translarna) for nonsense mutation Duchenne muscular dystrophy [internet]. CureDuchenne. 2025 [cited 2026 Jan 15]. Available from: https:\/\/cureduchenne.org\/research\/update-to-the-u-s-duchenne-community-on-the-ataluren-translarna-for-nonsense-mutation-duchenne-muscular-dystrophy\/"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep05635"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307798"},{"key":"e_1_3_4_70_1","unstructured":"HuidaGene Therapeutics Co. Ltd. An Investigator-initiated clinical study evaluating the CRISPR-hfCas12max gene editing therapy in the treatment of duchenne muscular dystrophy (DMD) [internet]. Report No.: nCT06594094. Available from clinicaltrials.gov; 2024 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06594094"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12735"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02052-1"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.01.007"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1514898"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2219839"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.07.002"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00036-X"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70165"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-025-05904-5"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.007"},{"key":"e_1_3_4_81_1","unstructured":"Masonic Cancer Center University of Minnesota. Phase I clinical trial of cell based therapy for duchenne muscular dystrophy [internet]. Report No.: nCT06692426. clinicaltrials.gov; 2025 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06692426"},{"key":"e_1_3_4_82_1","unstructured":"ENCell. Open-label dose-escalation phase 1 clinical trial to determine the safety and dose of EN001 in patients with duchenne muscular dystrophy(DMD) [internet]. Report No.: nCT05338099. clinicaltrials.gov; 2024 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05338099"},{"key":"e_1_3_4_83_1","unstructured":"ENCell. A multi-center randomized double-blind placebo-controlled phase 1\/2 trial to evaluate the efficacy and safety of EN001 in patients with duchenne muscular dystrophy [internet]. Report No.: nCT06328725. clinicaltrials.gov; 2024 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06328725"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.314"},{"key":"e_1_3_4_85_1","unstructured":"Satellos Bioscience Inc. A phase 2a randomized double-blind placebo-controlled dose comparison and exploratory efficacy study of orally administered SAT-3247 in ambulatory DMD patients [internet]. Report No.: nCT07287189. clinicaltrials.gov; 2026 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07287189"},{"key":"e_1_3_4_86_1","unstructured":"Satellos Bioscience Inc. An open-Label Long-term follow-up study of SAT-3247 in patients with duchenne muscular dystrophy (DMD) that participated in SAT-3247-CL-101 [internet]. Report No.: nCT06867107. clinicaltrials.gov; 2025 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06867107"},{"key":"e_1_3_4_87_1","unstructured":"Satellos Bioscience Inc. Phase 1 randomized double-blind placebo-controlled staggered parallel single and multiple ascending dose and food effect study to evaluate the safety and PK of oral SAT-3247 in healthy volunteers and participants with DMD [internet]. Report No.: nCT06565208. clinicaltrials.gov; 2025 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06565208"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-023-10620-3"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-025-11039-8"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00012-5"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006950"},{"key":"e_1_3_4_92_1","unstructured":"Manalac 3 min read | Tristan. Capricor plunges on FDA rejection of DMD cell therapy [internet]. BioSpace. 2025 [cited 2026 Jan 12]. Available from: https:\/\/www.biospace.com\/fda\/capricor-plunges-on-fda-rejection-of-dmd-cell-therapy"},{"key":"e_1_3_4_93_1","unstructured":"Capricor Inc. A phase 3 randomized double-blind placebo-controlled trial evaluating the efficacy and safety of human Allogeneic Cardiosphere-derived cells for the treatment of duchenne muscular dystrophy [internet]. Report No.: nCT05126758. clinicaltrials.gov; 2025 [cited 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05126758"},{"key":"e_1_3_4_94_1","unstructured":"Capricor therapeutics announces positive topline results from pivotal phase 3 HOPE-3 study of Deramiocel in duchenne muscular dystrophy [internet]. Capricor Ther. Inc; 2025 [cited 2026 Feb 2]. Available from: https:\/\/www.capricor.com\/investors\/news-events\/press-releases\/detail\/331\/capricor-therapeutics-announces-positive-topline-results"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-025-00394-2"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1177\/22143602241303357"},{"key":"e_1_3_4_98_1","unstructured":"Systemic treatment of Body-Wide duchenne muscular dystrophy symptoms - Konieczny - 2024 - clinical pharmacology & therapeutics - wiley online library [internet]. [cited 2026 Jan 7]. Available from: https:\/\/ascpt-onlinelibrary-wiley-com.dml.regis.edu\/doi\/10.1002\/cpt.3363"},{"key":"e_1_3_4_99_1","unstructured":"Inc CP. Cumberland pharmaceuticals shares phase 2 FIGHT DMD trial results at the parent project muscular dystrophy annual conference [internet]. [cited 2026 Jan 27]. Available from: https:\/\/www.prnewswire.com\/news-releases\/cumberland-pharmaceuticals-shares-phase-2-fight-dmd-trial-results-at-the-parent-project-muscular-dystrophy-annual-conference-302487504.html"},{"key":"e_1_3_4_100_1","unstructured":"PhD MM. FDA grants rare pediatric designation to (Z)-endoxifen for DMD [internet]. 2025 [cited 2026 Jan 8]. Available from: https:\/\/musculardystrophynews.com\/news\/fda-grants-rare-pediatric-designation-endoxifen-dmd\/"},{"key":"e_1_3_4_101_1","unstructured":"Research C for DE and. Accelerated approval program [internet]. FDA; 2025 [cited 2026 Feb 2]. Available from: https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/accelerated-approval-program"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-024-00645-7"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/cns3.20076"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2652459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:03:47Z","timestamp":1777017827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2652459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/14656566.2026.2652459"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2652459","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}